Home
NewsNewsFor the first time, the World Health Organization has officially listed the Ministry of Health, Labor, and Welfare/Pharmaceuticals and Medical Devices Agency (MHLW/PMDA) of Japan, Health Canada, and the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK as the new WHO-listed authorities (WLAs), a status that is granted to national authorities that meet the highest international regulatory benchmarks when it comes to medical products.
For the first time, the World Health Organization has officially listed the Ministry of Health, Labor, and Welfare/Pharmaceuticals and Medical Devices Agency (MHLW/PMDA) of Japan, Health Canada, and the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK as the new WHO-listed authorities (WLAs), a status that is granted to national authorities that meet the highest international regulatory benchmarks when it comes to medical products.
With these latest designations, WHO goes on to expand the growing list of WLAs, which now involves 39 agencies throughout the world, thereby supporting a broader and faster access to quality-assured medical products, especially in low- as well as middle-income countries.
Besides this, the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea, which is one of the first regulatory authorities to complete the WLA evaluation for medicines as well as vaccines in October 2023, has got its listing scope successfully expanded, therefore now covering all the regulatory functions.
According to Dr. Tedros Adhanom Ghebreyesus, who is the director-general of the World Health Organization, this recognition goes on to reflect the deep commitment of these authorities towards regulatory excellence. The designation as new WHO-listed authorities is not just a testament to their robust systems concerning regulations but also a crucial contribution that they make towards global public health. He added that robust and dependable regulators help in ensuring that people across the world have access to effective, safe, and high-quality medical products.
Fertility is a person’s ability to conceive children. In general, when a woman is unable to get pregnant even after at least one year of unprotected sex, she is considered to have infertility and her doctor will begin evaluating the possible causes.
Menopause can usher in a host of disruptive symptoms like hot flashes, night sweats and sleep problems. Hormone therapy promises relief. But many women wonder about taking it. That’s because the treatment, subject of a recent expert panel convened by the Food and Drug Administration, has long been shrouded in uncertainty.
With the partnership, PatientPoint’s waiting room and exam room screens will feature messaging that promotes MyHealthTeam’s platform, which serves over 27 million patients annually through an expanding network of more than 60 patient communities
In an age where customization is prized as well as friction is the enemy of efficiency, zero-click care – passive patient engagement by way of ambient sensing and IoT in hospitals
Explore the cost of IUI worldwide, comparing prices and factors aExplore the cost of IUI worldwide, comparing prices and factors aExplore the cost of IUI worldwide, comparing prices and factors a
Under the terms of the agreement, Exeltis will acquire exclusive rights to market and distribute Theranexus’ proprietary product across key regions, including the European Union, UK, Latin America, and selected Middle Eastern countries. This collaboration will target both Gaucher and Niemann-Pick type C diseases.
